HRP20110608T1 - Uporaba spojeva c-(2-fenil-cikloheksil)-metilamina za liječenje anksioznih poremećaja - Google Patents
Uporaba spojeva c-(2-fenil-cikloheksil)-metilamina za liječenje anksioznih poremećaja Download PDFInfo
- Publication number
- HRP20110608T1 HRP20110608T1 HR20110608T HRP20110608T HRP20110608T1 HR P20110608 T1 HRP20110608 T1 HR P20110608T1 HR 20110608 T HR20110608 T HR 20110608T HR P20110608 T HRP20110608 T HR P20110608T HR P20110608 T1 HRP20110608 T1 HR P20110608T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclohexyl
- dimethylaminomethyl
- phenol
- phenyl
- cyclohexylmethyl
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract 4
- JIRYWFYYBBRJAN-UHFFFAOYSA-N 3-[2-[(dimethylamino)methyl]cyclohexyl]phenol Chemical compound CN(C)CC1CCCCC1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-UHFFFAOYSA-N 0.000 claims abstract 7
- VTXTVLAQPBIPPF-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=CC(C2C(CCCC2)CN(C)C)=C1 VTXTVLAQPBIPPF-UHFFFAOYSA-N 0.000 claims abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- WMFQEDGHYPJQSG-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n-methylmethanamine Chemical compound CNCC1CCCCC1C1=CC=CC(OC)=C1 WMFQEDGHYPJQSG-UHFFFAOYSA-N 0.000 claims abstract 2
- WMRBLCTVXONZBT-UHFFFAOYSA-N 3-[2-(aminomethyl)cyclohexyl]phenol Chemical compound NCC1CCCCC1C1=CC=CC(O)=C1 WMRBLCTVXONZBT-UHFFFAOYSA-N 0.000 claims abstract 2
- KUGOVDMEUQXLRD-UHFFFAOYSA-N 3-[2-(methylaminomethyl)cyclohexyl]phenol Chemical compound CNCC1CCCCC1C1=CC=CC(O)=C1 KUGOVDMEUQXLRD-UHFFFAOYSA-N 0.000 claims abstract 2
- CKMPEIWYGQTXJB-UHFFFAOYSA-N 4-[2-[(dimethylamino)methyl]cyclohexyl]benzene-1,2-diol Chemical compound CN(C)CC1CCCCC1C1=CC=C(O)C(O)=C1 CKMPEIWYGQTXJB-UHFFFAOYSA-N 0.000 claims abstract 2
- FMGWPVLPVFJEAH-UHFFFAOYSA-N 6-[3-[2-[(dimethylamino)methyl]cyclohexyl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CN(C)CC1CCCCC1C1=CC=CC(OC2C(C(O)C(O)C(O2)C(O)=O)O)=C1 FMGWPVLPVFJEAH-UHFFFAOYSA-N 0.000 claims abstract 2
- NPZGGTZKFXTTSR-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]cyclohexyl]phenyl] hydrogen sulfate Chemical compound CN(C)CC1CCCCC1C1=CC=CC(OS(O)(=O)=O)=C1 NPZGGTZKFXTTSR-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- VTXTVLAQPBIPPF-HOCLYGCPSA-N 1-[(1r,2r)-2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine Chemical compound COC1=CC=CC([C@H]2[C@@H](CCCC2)CN(C)C)=C1 VTXTVLAQPBIPPF-HOCLYGCPSA-N 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- JIRYWFYYBBRJAN-ZFWWWQNUSA-N faxeladol Chemical compound CN(C)C[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 JIRYWFYYBBRJAN-ZFWWWQNUSA-N 0.000 claims 2
- WMFQEDGHYPJQSG-ZFWWWQNUSA-N 1-[(1r,2r)-2-(3-methoxyphenyl)cyclohexyl]-n-methylmethanamine Chemical compound CNC[C@@H]1CCCC[C@H]1C1=CC=CC(OC)=C1 WMFQEDGHYPJQSG-ZFWWWQNUSA-N 0.000 claims 1
- WMRBLCTVXONZBT-AAEUAGOBSA-N 3-[(1r,2r)-2-(aminomethyl)cyclohexyl]phenol Chemical compound NC[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 WMRBLCTVXONZBT-AAEUAGOBSA-N 0.000 claims 1
- KUGOVDMEUQXLRD-JSGCOSHPSA-N 3-[(1r,2r)-2-(methylaminomethyl)cyclohexyl]phenol Chemical compound CNC[C@@H]1CCCC[C@H]1C1=CC=CC(O)=C1 KUGOVDMEUQXLRD-JSGCOSHPSA-N 0.000 claims 1
- CKMPEIWYGQTXJB-STQMWFEESA-N 4-[(1r,2r)-2-[(dimethylamino)methyl]cyclohexyl]benzene-1,2-diol Chemical compound CN(C)C[C@@H]1CCCC[C@H]1C1=CC=C(O)C(O)=C1 CKMPEIWYGQTXJB-STQMWFEESA-N 0.000 claims 1
- FMGWPVLPVFJEAH-QXASIPDLSA-N 6-[3-[(1r,2r)-2-[(dimethylamino)methyl]cyclohexyl]phenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CN(C)C[C@@H]1CCCC[C@H]1C1=CC=CC(OC2C(C(O)C(O)C(O2)C(O)=O)O)=C1 FMGWPVLPVFJEAH-QXASIPDLSA-N 0.000 claims 1
- UMDGVFXQBMCYNZ-JSGCOSHPSA-N [(1r,2r)-2-(3-methoxyphenyl)cyclohexyl]methanamine Chemical compound COC1=CC=CC([C@H]2[C@@H](CCCC2)CN)=C1 UMDGVFXQBMCYNZ-JSGCOSHPSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 abstract 3
- 229940005513 antidepressants Drugs 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- LOMMOGHGUYMOEF-UHFFFAOYSA-N 1-[2-(3-methoxyphenyl)cyclohexyl]-n,n-dimethylmethanamine oxide Chemical compound COC1=CC=CC(C2C(CCCC2)C[N+](C)(C)[O-])=C1 LOMMOGHGUYMOEF-UHFFFAOYSA-N 0.000 abstract 1
- -1 3-(2-dimethylaminomethyl-cyclohexyl)-phenol N-oxide Chemical class 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 abstract 1
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 1
- 239000003402 opiate agonist Substances 0.000 abstract 1
- 230000000697 serotonin reuptake Effects 0.000 abstract 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10356362A DE10356362A1 (de) | 2003-11-28 | 2003-11-28 | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie von Angststörungen |
| PCT/EP2004/013439 WO2005051375A1 (de) | 2003-11-28 | 2004-11-26 | Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110608T1 true HRP20110608T1 (hr) | 2011-10-31 |
Family
ID=34609453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110608T HRP20110608T1 (hr) | 2003-11-28 | 2011-08-17 | Uporaba spojeva c-(2-fenil-cikloheksil)-metilamina za liječenje anksioznih poremećaja |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060258741A1 (ja) |
| EP (2) | EP1970060B9 (ja) |
| JP (1) | JP5013875B2 (ja) |
| AT (1) | ATE509626T1 (ja) |
| CA (1) | CA2546672C (ja) |
| CY (2) | CY1113348T1 (ja) |
| DE (1) | DE10356362A1 (ja) |
| DK (2) | DK1970060T3 (ja) |
| ES (2) | ES2362752T3 (ja) |
| HR (1) | HRP20110608T1 (ja) |
| PL (2) | PL1970060T3 (ja) |
| PT (2) | PT1686984E (ja) |
| SI (2) | SI1970060T1 (ja) |
| WO (1) | WO2005051375A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050182131A1 (en) * | 2002-07-19 | 2005-08-18 | Gruenenthal Gmbh | 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence |
| DE102005034974A1 (de) * | 2005-07-22 | 2007-04-19 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| DE102005034973A1 (de) * | 2005-07-22 | 2007-02-15 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| DE102005061428A1 (de) * | 2005-12-22 | 2007-08-16 | Grünenthal GmbH | Substituierte Cyclohexylmethyl-Derivate |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19525137C2 (de) | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
| US6387956B1 (en) * | 1999-03-24 | 2002-05-14 | University Of Cincinnati | Methods of treating obsessive-compulsive spectrum disorders |
| DE10059411A1 (de) * | 2000-11-30 | 2002-06-13 | Gruenenthal Gmbh | Verwendung von 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur Therapie der Harninkontinenz |
| DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| DE10146275A1 (de) * | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz |
| WO2003048113A1 (en) * | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
| DE10233048A1 (de) * | 2002-07-19 | 2004-01-29 | Grünenthal GmbH | Verwendung von 1-Phenyl-3dimethylamino-propanverbindungen zur Therapie von depressiven Symptomatiken |
| SI3241550T1 (sl) * | 2002-11-22 | 2020-11-30 | Grunenthal Gmbh | Uporaba (1R, 2R) -3- (3-dimetilimanino-1-etil-2-metil-propil)-fenola za zdravljenje vnetnih bolečin |
| DE10254785A1 (de) * | 2002-11-22 | 2004-06-03 | Grünenthal GmbH | Kombination ausgewählter Analgetika mit COX II-Inhibitoren |
| DE102005011517A1 (de) * | 2005-03-10 | 2006-09-21 | Grünenthal GmbH | Transdermales therapeutisches System zur Verabreichung von Analgetika |
| US20090104266A1 (en) * | 2005-09-15 | 2009-04-23 | Tobias Jung | 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation |
-
2003
- 2003-11-28 DE DE10356362A patent/DE10356362A1/de not_active Ceased
-
2004
- 2004-11-26 PL PL08008351T patent/PL1970060T3/pl unknown
- 2004-11-26 AT AT04819227T patent/ATE509626T1/de active
- 2004-11-26 PL PL04819227T patent/PL1686984T3/pl unknown
- 2004-11-26 JP JP2006540395A patent/JP5013875B2/ja not_active Expired - Fee Related
- 2004-11-26 DK DK08008351.2T patent/DK1970060T3/da active
- 2004-11-26 PT PT04819227T patent/PT1686984E/pt unknown
- 2004-11-26 ES ES04819227T patent/ES2362752T3/es active Active
- 2004-11-26 WO PCT/EP2004/013439 patent/WO2005051375A1/de active Application Filing
- 2004-11-26 ES ES08008351T patent/ES2390931T3/es active Active
- 2004-11-26 SI SI200431926T patent/SI1970060T1/sl unknown
- 2004-11-26 CA CA2546672A patent/CA2546672C/en not_active Expired - Fee Related
- 2004-11-26 PT PT08008351T patent/PT1970060E/pt unknown
- 2004-11-26 EP EP08008351A patent/EP1970060B9/de not_active Not-in-force
- 2004-11-26 EP EP04819227A patent/EP1686984B1/de active Active
- 2004-11-26 SI SI200431677T patent/SI1686984T1/sl unknown
- 2004-11-26 DK DK04819227.2T patent/DK1686984T3/da active
-
2006
- 2006-05-25 US US11/440,005 patent/US20060258741A1/en not_active Abandoned
-
2009
- 2009-09-14 US US12/558,896 patent/US8084497B2/en not_active Expired - Fee Related
-
2010
- 2010-06-09 US US12/797,408 patent/US20100249225A1/en not_active Abandoned
-
2011
- 2011-06-21 CY CY20111100588T patent/CY1113348T1/el unknown
- 2011-08-17 HR HR20110608T patent/HRP20110608T1/hr unknown
-
2012
- 2012-09-28 CY CY20121100904T patent/CY1113162T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5013875B2 (ja) | 2012-08-29 |
| PT1970060E (pt) | 2012-10-02 |
| US20100004341A1 (en) | 2010-01-07 |
| CA2546672C (en) | 2013-01-22 |
| EP1686984B1 (de) | 2011-05-18 |
| EP1686984A1 (de) | 2006-08-09 |
| CA2546672A1 (en) | 2005-06-09 |
| SI1686984T1 (sl) | 2011-07-29 |
| DK1970060T3 (da) | 2012-10-01 |
| CY1113162T1 (el) | 2016-04-13 |
| US20060258741A1 (en) | 2006-11-16 |
| US8084497B2 (en) | 2011-12-27 |
| SI1970060T1 (sl) | 2012-10-30 |
| EP1970060B9 (de) | 2013-01-09 |
| PL1970060T3 (pl) | 2012-11-30 |
| CY1113348T1 (el) | 2016-06-22 |
| EP1970060B1 (de) | 2012-08-29 |
| ATE509626T1 (de) | 2011-06-15 |
| ES2362752T3 (es) | 2011-07-12 |
| PT1686984E (pt) | 2011-05-30 |
| US20100249225A1 (en) | 2010-09-30 |
| ES2390931T3 (es) | 2012-11-19 |
| EP1970060A2 (de) | 2008-09-17 |
| JP2007512288A (ja) | 2007-05-17 |
| DE10356362A1 (de) | 2005-06-23 |
| WO2005051375A1 (de) | 2005-06-09 |
| EP1970060A3 (de) | 2009-04-15 |
| DK1686984T3 (da) | 2011-06-20 |
| PL1686984T3 (pl) | 2011-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6001884A (en) | Calcium receptor-active molecules | |
| AU709303B2 (en) | Calcium receptor-active compounds | |
| CA2173747C (en) | Calcium receptor-active arylalkyl amines | |
| HRP20110608T1 (hr) | Uporaba spojeva c-(2-fenil-cikloheksil)-metilamina za liječenje anksioznih poremećaja | |
| US20100081718A1 (en) | Combinations comprising alpha-2-delta ligands | |
| BRPI0407256A (pt) | Utilização do enantiÈmero (1s,2r) do milnacipran para a preparação de um medicamento | |
| CA2652421A1 (en) | Treatment for depressive disorders | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| CO5680411A2 (es) | Compuestos del 1-fenil-2-dimetilamino-metil-ciclohexano, para la terapia de sintomatologia depresiva, dolor e incontinencia | |
| US20090318451A1 (en) | Morpholine dopamine agonists for the treatment of pain | |
| EP4161900A1 (en) | Cannabidiolic acid (cbda) derivatives and uses thereof | |
| JP2011519839A (ja) | ドーパミン神経伝達のモジュレーター | |
| JP2008532992A (ja) | ベンゾキサゾシンおよびそれらの治療的使用 | |
| JP7343641B2 (ja) | 神経伝達物質放出剤としてのビニローグフェネチルアミン | |
| AU747853B2 (en) | Calcium receptor-active compounds |